Anti-Rheumatic Drugs - Mexico

Mexico

Mexico is expected to experience significant growth in the Anti-Rheumatic Drugs market.
By 2025, the projected revenue is estimated to reach €163.70m in Mexico.
This is anticipated to be driven by an annual growth rate (CAGR 2025-2029) of 0.49%, which will result in a market volume of €166.90m by 2029 in the country.
In comparison to other countries globally, United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market.
In 2025, the revenue United States is projected to reach €31,210.00m.
Despite the high prevalence of rheumatic diseases in Mexico, access to affordable anti-rheumatic drugs remains a significant challenge for many patients.

Key regions: Germany, United States, India, Japan, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Rheumatic Drugs market in Mexico has been experiencing steady growth in recent years.

Customer preferences: Mexican customers have shown a growing interest in Anti-Rheumatic Drugs due to the rising prevalence of rheumatic diseases in the country. Additionally, the increasing availability of these drugs in the market has made them more accessible to the public. Patients suffering from rheumatic diseases are willing to pay a premium for drugs that provide relief from their symptoms.

Trends in the market: The Mexican Anti-Rheumatic Drugs market has been experiencing a shift towards biologic drugs as they offer better efficacy and safety profiles than traditional disease-modifying antirheumatic drugs (DMARDs). There has also been a trend towards combination therapy, where biologic drugs are used in combination with DMARDs to achieve better outcomes. The market has also seen an increase in the number of biosimilars being introduced, which has led to increased competition and lower prices.

Local special circumstances: Mexico has a high prevalence of rheumatic diseases, with over 5 million people suffering from them. Additionally, the country has a large aging population, which is more susceptible to these diseases. The Mexican government has recognized the importance of addressing this issue and has implemented various initiatives to improve access to healthcare services and medications. This has led to an increase in demand for Anti-Rheumatic Drugs in the country.

Underlying macroeconomic factors: Mexico has a growing economy, which has led to an increase in disposable income and a rise in healthcare spending. Additionally, the country has a large pharmaceutical industry, which has helped to drive innovation and competition in the market. The government has also implemented policies to encourage foreign investment in the sector, which has led to increased research and development activities. These factors have contributed to the growth of the Anti-Rheumatic Drugs market in Mexico.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.